ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2018
Height, Obesity, and the Risk of
Open access · bronzeAbstract read
In one paragraph
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 17% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Etiology of prostate cancer with the TMPRSS2:ERG fusion: A systematic review of risk factors.International journal of cancer · 2025Pooled it
- Targeting obesity, metabolic syndrome, and prostate cancer: GLP-1 agonists as emerging therapeutic agents.Discover oncology · 2025Review
- Modifiable risk factors for subsequent lethal prostate cancer among men with an initially negative prostate biopsy.British journal of cancer · 2023Article
- Joint associations between established genetic susceptibility loci, pesticide exposures, and risk of prostate cancer.Environmental research · 2023Article
- Associations between Etiologic or Prognostic Tumor Tissue Markers and Neighborhood Contextual Factors in Male Health Professionals Diagnosed with Prostate Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2023Article
- Transcriptomes of Prostate Cancer with TMPRSS2:ERG and Other ETS Fusions.Molecular cancer research : MCR · 2023Article
- Machine learning model for the prediction of prostate cancer in patients with low prostate-specific antigen levels: A multicenter retrospective analysis.Frontiers in oncology · 2022Article
- Epidemiology and genomics of prostate cancer in Asian men.Nature reviews. Urology · 2021Review
- Association of Prediagnostic Blood Metabolomics with Prostate Cancer Defined by ERG or PTEN Molecular Subtypes.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2021Article
- Molecular Basis of Prostate Cancer and Natural Products as Potential Chemotherapeutic and Chemopreventive Agents.Frontiers in pharmacology · 2021Review
- Family history of prostate cancer and the incidence of ERG- and phosphatase and tensin homolog-defined prostate cancer.International journal of cancer · 2020Article
- Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020Article
- Cancer Progress and Priorities: Prostate Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020Article
- A Prospective Study of the Association between Physical Activity and Risk of Prostate Cancer Defined by Clinical Features and TMPRSS2:ERG.European urology · 2019Article
- Is There Etiologic Heterogeneity between Subtypes of Childhood Acute Lymphoblastic Leukemia? A Review of Variation in Risk by Subtype.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2019Review
- Corpora amylacea in prostatectomy tissue and associations with molecular, histological, and lifestyle factors.The Prostate · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 1 institution in 1 country.
Rebecca E Graff *Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California. Rebecca.Graff@ucsf.edu.
Thomas U Ahearn *Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Andreas PetterssonDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Ericka M EbotDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Travis GerkeDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Kathryn L PenneyDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Kathryn M WilsonDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Sarah C MarktDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Claire H PernarDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Amparo G Gonzalez-FelicianoDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Mingyang SongDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Rosina T LisDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Daniel R SchmidtDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts.
Matthew G Vander HeidenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Michelangelo FiorentinoPathology Unit, Addarii Institute, S. Orsola-Malpighi Hospital, Bologna, Italy.
Edward L GiovannucciDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Massimo LodaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Lorelei A MucciDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Dana-Farber Cancer Institute · US
Funding
Statistical MethodsP01CA087969 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ROSNER, BERNARD A · 2000 to 2019
$77.8MTumor and Circulating Markers as Links Between Obesity and Lethal Prostate CanceP50CA090381 · NCI · DANA-FARBER CANCER INSTITUTE · PI KANTOFF, PHILIP W · 2002 to 2017
$36.2MLong Term Multidisciplinary Study of Cancer in Women: The Nurses Health StudyUM1CA186107 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ELIASSEN, A. HEATHER, STAMPFER, MEIR · 2014 to 2023
$22.3MTraining Program in Cancer EpidemiologyT32CA009001 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI A. Heather Eliassen, Meir Stampfer · 1985 to 2026
$17.3MCancer Epidemiology Cohort in Male Health ProfessionalsU01CA167552 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Lorelei Mucci, Walter C. Willett · 2017 to 2026
$17.0MTraining in Molecular& Genetic Epidemiology of CancerR25CA112355 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WITTE, JOHN S. · 2005 to 2018
$6.5MMolecular Link Between Metabolic Syndrome and Prostate CancerR01CA131945 · NCI · DANA-FARBER CANCER INST · PI LODA, MASSIMO · 2008 to 2018
$4.0MSex-Hormones and the TMPRSS2: ERG Fusion in Prostate Cancer ProgressionR01CA136578 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI MUCCI, LORELEI · 2009 to 2013
$1.7MHoward Hughes Medical InstituteNCI NIH HHS P01 CA087969NCI NIH HHS P50 CA090381NCI NIH HHS R01 CA131945NCI NIH HHS R01 CA136578NCI NIH HHS R25 CA112355NCI NIH HHS T32 CA009001NCI NIH HHS U01 CA167552NCI NIH HHS UM1 CA186107
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAgedBody HeightBody Mass IndexBody WeightFollow-Up StudiesHumansMaleMiddle AgedObesityOncogene Proteins, FusionProspective StudiesProstatic NeoplasmsRisk FactorsTranscriptional Regulator ERGERG protein, humanOncogene Proteins, FusionTMPRSS2-ERG fusion protein, humanTranscriptional Regulator ERG
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.